These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32380464)

  • 1. Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.
    Chumsri S; Sokol ES; Soyano-Muller AE; Parrondo RD; Reynolds GA; Nassar A; Thompson EA
    J Natl Compr Canc Netw; 2020 May; 18(5):517-521. PubMed ID: 32380464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
    Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population.
    Scobie MR; Zhou KI; Ahmed S; Kelley MJ
    JCO Precis Oncol; 2023 Sep; 7():e2300176. PubMed ID: 38039430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
    Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
    Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
    Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
    JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
    Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.
    Brasó-Maristany F; Sansó M; Chic N; Martínez D; González-Farré B; Sanfeliu E; Ghiglione L; Carcelero E; Garcia-Corbacho J; Sánchez M; Soy D; Jares P; Peg V; Saura C; Muñoz M; Prat A; Vivancos A
    Front Oncol; 2021; 11():710596. PubMed ID: 34616675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
    Domblides C; Leroy K; Monnet I; Mazières J; Barlesi F; Gounant V; Baldacci S; Mennecier B; Toffart AC; Audigier-Valette C; Doucet L; Giroux-Leprieur E; Guisier F; Ricordel C; Molinier O; Perol M; Pichon E; Robinet G; Templement-Grangerat D; Ruppert AM; Rabbe N; Antoine M; Wislez M
    J Thorac Oncol; 2020 May; 15(5):860-866. PubMed ID: 31991225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.
    Andrews MC; Li G; Graf RP; Fisher VA; Mitchell J; Aboosaiedi A; O'Rourke H; Shackleton M; Iddawela M; Oxnard GR; Huang RSP
    JCO Precis Oncol; 2024 Jun; 8():e2300640. PubMed ID: 38848517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
    Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
    Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
    Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
    Jang BS; Han W; Kim IA
    Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMB or not TMB as a biomarker: That is the question.
    Addeo A; Friedlaender A; Banna GL; Weiss GJ
    Crit Rev Oncol Hematol; 2021 Jul; 163():103374. PubMed ID: 34087341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.